GPRC5D and neoplasm: To note, Ramantamig (simultaneously targeting BCMA, GPRC5D tumour-associated antigens along with CD3 receptor on effector T-cells) displayed enhanced anti-tumour activity against multiple myeloma in in vitro, ex vivo and in vivo settings (80).